HighTower Advisors
CNTX icon

HighTower Advisors’s Context Therapeutics CNTX Stock Holding History

HighTower Advisors’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.7K Sell
125,852
-300
-0.2% -$608 ﹤0.01% 3695
2026
Q1 		$331K Buy
126,152
+300
+0.2% +$701 ﹤0.01% 3083
2025
Q4 		$185K Hold
125,852
– – ﹤0.01% 3400
2025
Q3 		$122K Hold
125,852
– – ﹤0.01% 3506
2025
Q2 		$82.5K Hold
125,852
– – ﹤0.01% 3500
2025
Q1 		$77K Hold
125,852
– – ﹤0.01% 3402
2024
Q4 		$132K Hold
125,852
– – ﹤0.01% 3312
2024
Q3 		$247K Hold
125,852
– – ﹤0.01% 2967
2024
Q2 		$252K Hold
125,852
– – ﹤0.01% 2859
2024
Q1 		$174K Hold
125,852
– – ﹤0.01% 3025
2023
Q4 		$142K Hold
125,852
– – ﹤0.01% 3106
2023
Q3 		$190K Hold
125,852
– – ﹤0.01% 2934
2023
Q2 		$201K Hold
125,852
– – ﹤0.01% 2865
2023
Q1 		$71K Hold
125,852
– – ﹤0.01% 2999
2022
Q4 		$82K Hold
125,852
– – ﹤0.01% 2964
2022
Q3 		$140K Hold
125,852
– – ﹤0.01% 2692
2022
Q2 		$267K Buy
+125,852
New +$236K ﹤0.01% 2436

Other funds holding CNTX

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

HighTower Advisors's CNTX Position: Q2 2026 in Review

HighTower Advisors reduced its Context Therapeutics (CNTX) stake by 0.24% in Q2 2026, selling an estimated $608 and leaving 125,852 shares worth $69.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3695.

HighTower Advisors first reported a position in CNTX in Q2 2022 and has held it in 17 quarters since. The position peaked at $331K in Q1 2026. 43 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • HighTower Advisors held 125,852 shares of Context Therapeutics worth $69.7K as of Q2 2026.
  • HighTower Advisors sold 300 Context Therapeutics shares in Q2 2026, an estimated $608.
  • Context Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3695 holding.
  • HighTower Advisors first reported a position in Context Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • HighTower Advisors's Context Therapeutics position peaked at $331K in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.